[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE540037T1 - Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten - Google Patents

Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten

Info

Publication number
ATE540037T1
ATE540037T1 AT08758202T AT08758202T ATE540037T1 AT E540037 T1 ATE540037 T1 AT E540037T1 AT 08758202 T AT08758202 T AT 08758202T AT 08758202 T AT08758202 T AT 08758202T AT E540037 T1 ATE540037 T1 AT E540037T1
Authority
AT
Austria
Prior art keywords
compounds
treatment
cycloalkyl
aryl
optionally substituted
Prior art date
Application number
AT08758202T
Other languages
English (en)
Inventor
Jakob Felding
Morten Syrensen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Application granted granted Critical
Publication of ATE540037T1 publication Critical patent/ATE540037T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT08758202T 2007-04-16 2008-04-16 Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten ATE540037T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91202007P 2007-04-16 2007-04-16
PCT/DK2008/000135 WO2008125111A1 (en) 2007-04-16 2008-04-16 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Publications (1)

Publication Number Publication Date
ATE540037T1 true ATE540037T1 (de) 2012-01-15

Family

ID=39539479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08758202T ATE540037T1 (de) 2007-04-16 2008-04-16 Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten

Country Status (7)

Country Link
US (1) US8829190B2 (de)
EP (1) EP2146989B1 (de)
JP (1) JP2010523725A (de)
CN (1) CN101679428A (de)
AT (1) ATE540037T1 (de)
ES (1) ES2380395T3 (de)
WO (1) WO2008125111A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ593595A (en) * 2008-12-19 2013-07-26 Leo Pharma As Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
EP2417135A1 (de) * 2009-04-07 2012-02-15 Schering Corporation Substituierte triazolopyridine und analoga davon
MX2011012961A (es) 2009-06-05 2012-01-30 Cephalon Inc Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina.
EP2683376B1 (de) 2011-03-07 2018-11-28 Celgene Corporation Verfahren zur behandlung von erkrankungen mit isoindolinverbindungen
RU2630699C2 (ru) 2011-12-21 2017-09-12 Лео Фарма А/С [1,2,4]триазолопиридины и их применение в качестве ингибиторов фосфодиэстеразы
WO2014206903A1 (en) 2013-06-25 2014-12-31 Leo Pharma A/S METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105219B9 (de) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamine als lsd1-hemmer
BR112016018555B1 (pt) 2014-02-13 2024-01-23 Incyte Holdings Corporation Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
WO2015123465A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
EA035534B1 (ru) 2015-08-12 2020-06-30 Инсайт Корпорейшн Соли ингибитора lsd1
JP6999574B2 (ja) 2016-04-22 2022-01-18 インサイト・コーポレイション Ｌｓｄ１阻害剤の製剤
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT771794E (pt) 1995-05-19 2006-09-29 Kyowa Hakko Kogyo Kk Compostos heterociclicos contendo oxigenio
WO1997048697A1 (en) * 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO1998022455A1 (fr) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Composes heterocycliques d'oxygene
CA2515190A1 (en) * 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
EP1799680A2 (de) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridinderivate als antibakterielle mittel

Also Published As

Publication number Publication date
EP2146989A1 (de) 2010-01-27
JP2010523725A (ja) 2010-07-15
EP2146989B1 (de) 2012-01-04
WO2008125111A1 (en) 2008-10-23
US8829190B2 (en) 2014-09-09
CN101679428A (zh) 2010-03-24
ES2380395T3 (es) 2012-05-11
US20100113442A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
ATE540037T1 (de) Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
HK1138262A1 (en) Novel phosphodiesterase inhibitors
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
MY177250A (en) Novel nicotinamide derivative or salt thereof
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
NZ610312A (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
AR083842A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
MA32460B1 (fr) Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
MX2009003227A (es) Moduladores de los receptores de glutamato metabotropicos 5(mglur5).
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
MX2013012555A (es) Inhibidores novedosos de rock.
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
RU2015150120A (ru) Соединение дикарбоновой кислоты